Publications
Detailed Information
Dimethyl lithospermate B, an extract of Danshen, suppresses arrhythmogenesis associated with the Brugada syndrome
Cited 74 time in
Web of Science
Cited 86 time in Scopus
- Authors
- Issue Date
- 2005-03-15
- Publisher
- American Heart Association
- Citation
- Circulation. 2006 Mar 21;113(11):1393-400. Epub 2006 Mar 13.
- Keywords
- Animals ; Arrhythmias, Cardiac/etiology/*prevention & control ; Biological Transport/drug effects ; Calcium Channel Blockers/toxicity ; Dogs ; Drug Evaluation, Preclinical ; Drugs, Chinese Herbal/isolation & purification/*therapeutic use ; Electrocardiography/drug effects ; Female ; Male ; Pinacidil/toxicity ; Plant Extracts/isolation & purification/*therapeutic use ; Plant Roots/chemistry ; Potassium Channels/agonists ; Salvia miltiorrhiza/*chemistry ; Sodium/metabolism ; Sodium Channel Blockers/toxicity ; Sodium Channels/*agonists/physiology ; Stimulation, Chemical ; Terfenadine/toxicity ; Verapamil/toxicity
- Abstract
- BACKGROUND: Dimethyl lithospermate B (dmLSB) is an extract of Danshen, a traditional Chinese herbal remedy, which slows inactivation of INa, leading to increased inward current during the early phases of the action potential (AP). We hypothesized that this action would be antiarrhythmic in the setting of Brugada syndrome. METHODS AND RESULTS: The Brugada syndrome phenotype was created in canine arterially perfused right ventricular wedge preparations with the use of either terfenadine or verapamil to inhibit INa and ICa or pinacidil to activate IK-ATP. AP recordings were simultaneously recorded from epicardial and endocardial sites together with an ECG. Terfenadine, verapamil, and pinacidil each induced all-or-none repolarization at some epicardial sites but not others, leading to ST-segment elevation as well as an increase in both epicardial and transmural dispersions of repolarization (EDR and TDR, respectively) from 12.9+/-9.6 to 107.0+/-54.8 ms and from 22.4+/-8.1 to 82.2+/-37.4 ms, respectively (P<0.05; n=9). Under these conditions, phase 2 reentry developed as the epicardial AP dome propagated from sites where it was maintained to sites at which it was lost, generating closely coupled extrasystoles and ventricular tachycardia and fibrillation. Addition of dmLSB (10 micromol/L) to the coronary perfusate restored the epicardial AP dome, reduced EDR and TDR to 12.4+/-18.1 and 24.4+/-26.7 ms, respectively (P<0.05; n=9), and abolished phase 2 reentry-induced extrasystoles and ventricular tachycardia and fibrillation in 9 of 9 preparations. CONCLUSIONS: Our data suggest that dmLSB is effective in eliminating the arrhythmogenic substrate responsible for the Brugada syndrome and that it deserves further study as a pharmacological adjunct to implanted cardioverter/defibrillator usage.
- ISSN
- 1524-4539 (Electronic)
- Language
- English
- URI
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16534004
https://hdl.handle.net/10371/28226
- Files in This Item:
- Appears in Collections:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.